Abrogation of HnRNP L enhances anti-PD-1 therapy efficacy via diminishing PD-L1 and promoting CD8(+) T cell-mediated ferroptosis in castration-resistant prostate cancer

Owing to incurable castration-resistant prostate cancer (CRPC) ultimately developing after treating with androgen deprivation therapy (ADT), it is vital to devise new therapeutic strategies to treat CRPC. Treatments that target programmed cell death protein 1 (PD-1) and programmed death ligand-1 (PD...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Xumin, Zou, Libin, Liao, Hangyu, Luo, Junqi, Yang, Taowei, Wu, Jun, Chen, Wenbin, Wu, Kaihui, Cen, Shengren, Lv, Daojun, Shu, Fangpeng, Yang, Yu, Li, Chun, Li, Bingkun, Mao, Xiangming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897216/
https://www.ncbi.nlm.nih.gov/pubmed/35256940
http://dx.doi.org/10.1016/j.apsb.2021.07.016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897216/
https://www.ncbi.nlm.nih.gov/pubmed/35256940
http://dx.doi.org/10.1016/j.apsb.2021.07.016

Ejemplares similares